title: Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.
authors.affiliation: Vanderbilt University Medical Center, Nashville, TN. Electronic address: Emily.hon@vanderbilt.edu.
authors.forename: Emily H
authors.initials: EH
authors.lastname: Castellanos
authors.affiliation: Stanford University Medical Center, Stanford, CA.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Rivera
authors.affiliation: Stanford University Medical Center, Stanford, CA.
authors.forename: Heather
authors.initials: H
authors.lastname: Wakelee
authors.affiliation: Vanderbilt University Medical Center, Nashville, TN.
authors.forename: Leora
authors.initials: L
authors.lastname: Horn
mesh_terms: D000077716:Afatinib; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D000077544:Panitumumab; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D011799:Quinazolines; D000077716:Afatinib; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors